Amicus Therapeutics (FOLD) investor relations material

Executive summary

• BioMarin will acquire Amicus Therapeutics for $14.50 per share in cash, totaling approximately $4.8 billion, representing a 33% premium to the last close and higher premiums to recent averages.

• The transaction is unanimously approved by both boards and expected to close in Q2 2026, subject to regulatory and shareholder approvals.

• The acquisition adds two high-growth rare disease therapies, Galafold and Pombiliti + Opfolda, to BioMarin’s portfolio, with combined revenues of $599 million over the past four quarters.

• The deal is expected to accelerate revenue growth, be accretive to Non-GAAP EPS within 12 months post-close, and substantially accretive by 2027.

• BioMarin will finance the deal with cash and $3.7 billion in non-convertible debt; the transaction is not subject to financing conditions.

Voting matters and shareholder proposals

• Amicus stockholders will vote on the merger at a special meeting; approval by a majority of outstanding shares is required.

• The proxy statement will include the board’s recommendation, fairness opinions, and details on the transaction.

• No other substantive proposals are included for shareholder action at the meeting.

Board of directors and corporate governance

• Both companies’ boards unanimously approved the merger agreement.

• Amicus’ board recommends shareholders vote in favor of the transaction.

• Post-merger, Amicus will become a wholly owned subsidiary of BioMarin, with its certificate of incorporation and bylaws amended accordingly.

• An amendment to Amicus’ bylaws establishes Delaware courts as the exclusive forum for certain legal actions.